synchronous gastric cancer
Recently Published Documents


TOTAL DOCUMENTS

25
(FIVE YEARS 5)

H-INDEX

5
(FIVE YEARS 0)

2021 ◽  
Vol 9 (10) ◽  
Author(s):  
Masashi Inoue ◽  
Keishi Hakoda ◽  
Hiroyuki Sawada ◽  
Ryuichi Hotta ◽  
Ichiro Ohmori ◽  
...  

Author(s):  
Shuichi Fukuda ◽  
Tomoko Wakasa ◽  
Hitoshi Hanamoto ◽  
Taichi Koyama ◽  
Yoshio Ohta ◽  
...  

AbstractThis report presents an extremely rare case of synchronous gastric cancer and primary adrenal diffuse large B-cell lymphoma (DLBCL). An 82-year-old man underwent computed tomography, which revealed a heterogeneous appearing and hypodense adrenal mass and a gastric mass with no enlarged lymph nodes in the neck, mediastinum, abdomen, and inguinal region. Upper gastrointestinal endoscopy revealed a protruding gastric tumor. The specimens obtained from endoscopic biopsy were histologically confirmed to be adenocarcinoma. The hormonal findings eliminated functional adrenal tumor. The patient underwent distal gastrectomy with regional lymph node resection for gastric cancer and incisional biopsy of the adrenal mass. Based on the pathological findings, diagnoses of mixed mucinous and tubular adenocarcinomas of the stomach and adrenal DLBCL were confirmed. Postoperation, the patient received rituximab combined with low-dose doxorubicin, cyclophosphamide, vincristine, and prednisone (R-miniCHOP). Six courses of R-miniCHOP were planned, but were completed in only one course at the patient’s request. The patient died 2 months after surgery.


Author(s):  
Masashi Inoue ◽  
Keishi Hakoda ◽  
Hiroyuki Sawada ◽  
Ryuichiro Hotta ◽  
Ichiro Omori ◽  
...  

Gastric cancer was diagnosed with dilation of the main pancreatic duct. SPACE revealed adenocarcinoma, total gastrectomy with distal pancreatectomy were underwent. More case reports are needed to determine whether adjuvant chemotherapy is indicated for patients with PCIS and whether the extent of lymph node dissection can be safely reduced.


In Vivo ◽  
2021 ◽  
Vol 35 (2) ◽  
pp. 913-918
Author(s):  
TSUTOMU NAMIKAWA ◽  
MASAHIRO MAEDA ◽  
KEIICHRO YOKOTA ◽  
NOBUHISA TANIOKA ◽  
JUN IWABU ◽  
...  

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Shunji Endo ◽  
Yoshinori Fujiwara ◽  
Koji Kurose ◽  
Masaharu Higashida ◽  
Hisako Kubota ◽  
...  

Abstract Background Nivolumab is effective for gastric cancer and lung cancer, but complete response is rare. We experienced a case of synchronous gastric cancer and lung cancer who was treated by nivolumab and laparoscopic gastrectomy. Case presentation A 63-year-old male consulted our institution and was found to have gastric cancer cT1(SM)N0M0 Stage IA and lung cancer cT2N2M1(PUL) Stage IV. He received eight chemotherapy treatments plus radiation, but the lung disease remained progressive. Finally, he received nivolumab therapy and complete response of both cancers was obtained. The gastric cancer recurred, but was successfully treated by laparoscopic gastrectomy. The resected specimen revealed three lesions, each being pT1aN0M0 Stage IA. The primary gastric cancer seemed to have completely vanished without scarring. Conclusions This was thought to be a rare case of gastric cancer recurrence after complete response of gastric cancer and lung cancer to nivolumab.


2020 ◽  
Vol 3 (1) ◽  
pp. 67-70
Author(s):  
Huanji Xu ◽  
Sheng Zhou ◽  
Qiancheng Hu ◽  
Dan Cao

Abstract Nearly one-fifth of patients diagnosed with gastrointestinal stromal tumors (GISTs) simultaneously experience a second primary tumor. In particular, coexistence of gastric GISTs and gastric cancer is relatively more common. However, the optimal treatment for advanced GIST with gastric cancer is largely unknown. We report a case of simultaneous occurrence of gastric GIST and gastric cancer that benefited from apatinib. After first-line imatinib and S-1 treatment for 6 months, the GIST and the gastric cancer both progressed. The patient was then treated with apatinib, exhibiting a partial response (PR) both in the GIST and the gastric cancer at 7 months, and continuous PR so far with well-controlled toxic effects of hypertension. Progression-free survival reached 10 months. In view of the relatively high incidence of advanced GIST with synchronous gastric cancer, therapy to simultaneously treat the two kinds of tumors is urgently needed. Apatinib provides promising and well-tolerated therapy for GISTs with synchronous gastric cancer refractory to chemotherapy combined with imatinib.


2017 ◽  
Vol 9 (8) ◽  
pp. 327 ◽  
Author(s):  
Narihiro Shibukawa ◽  
Shohei Ouchi ◽  
Shuji Wakamatsu ◽  
Yuhei Wakahara ◽  
Akira Kaneko

Sign in / Sign up

Export Citation Format

Share Document